• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® ADPR Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • CD38 Assay System
      • PARG Assay System
      • TREX1 Assay System
      • POLQ Helicase ATPase Assay System
      • WRN Helicase ATPase Assay System
    • Recombinant Enzymes
      • Human CD38 Enzyme
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human PARG Enzyme
      • Human POLQ Helicase Enzyme
      • Human TREX1 Enzyme
      • Human WRN Helicase Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • ATPase Profiling Services
    • GTPase Profiling Services
    • Thermal Shift Assay Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • METTL3/METTL14 Assays – Application
      • MLL4 Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
      • PRMT5 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay System
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
      • PARG Assay System
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • p97 Assays – Application
      • Ketohexokinase Assays – Application
      • WRN Helicase ATPase Assay System
      • POLQ Helicase ATPase Assay System
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
      • WRN Exonuclease Assays – Application
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
      • DNA Damage Response and Innate Immunity
    • Technical Support
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

B4GalT1 – A Druggable Target for the Treatment of Glioblastoma

by Bellbrook Labs / Tuesday, 21 September 2021 / Published in Emerging Targets, HTS Assays
B4GalT1 A Target to Stop Glioblastoma

Multi-faceted Properties of B4GalT1

Beta-1,4-Galactosyltransferase 1 (B4GalT1) belongs to the galactosyltransferase (GalT) family of enzymes that transfer galactose from uridine-diphosphate-α-D-galactose (UDP-Gal) to an acceptor sugar molecule. B4GalT1 is a critical enzyme in galactose metabolism.

One of the first GalT to be characterized biochemically, B4GalT1, was also involved in lactose production by interacting with α-lactalbumin during lactation1. However, more evidence has surfaced over the years illustrating B4GalT1’s role in other physiological processes such as aging2.

 

The Intimate Relationship Between B4GalT1 and Human Cancers

Several new studies have linked B4GalT1 expression to some forms of cancer. B4GalT1 was recently found to be involved in the proliferation and maintenance of cancer stem cells of lung adenocarcinoma3. Another study reported that high B4GalT1 expression in bladder cancer patients was also observed to correlate with low overall survival and expression of inhibitory receptor signals PD-1 and CTLA4. The effectiveness of adjuvant chemotherapy was also found to be higher in bladder cancer patients with lower expression levels of B4GalT14. Elevated B4GalT1 levels were also seen in megakaryocytes from myeloproliferative neoplasms5. Therefore B4GalT1 seems to play an essential role in human cancers, although more work has to be done to thoroughly examine the underlying mechanisms contributing to this relationship.

Targeting B4GalT1 for the Treatment of Glioblastoma

Glioblastoma multiforme (GBM), also known as glioblastoma, is the most aggressive and common form of glioma (a tumor that occurs in the brain and spine)6. Glioblastoma is a fast-growing, grade 4 glioma. Most patients with glioblastoma typically do not survive for more than a year. Due to the tumor’s complexity, glioblastoma remains an incurable disease, and treatment options are still relatively limited.

The involvement of B4GalT1 in glioblastoma is relatively unknown. However, a group of researchers reported for the first time that B4GalT1 expression was elevated in glioblastoma tumor tissue and human primary glioblastoma cells (U87)7. By reducing the expression of B4GalT1 in vitro, the proliferative and migratory capacity of U87 cells was suppressed. Mice injected with U87 cells expressing lower levels of B4GalT1 developed significantly smaller tumors and had a better survival rate than mice injected with normal U87 cells. They also discovered that underlying this phenomenon was that lower B4GalT1 expression induces apoptosis and autophagy of glioblastoma both in vitro and in vivo, therefore promoting cancer cell death. Hence, B4GalT1 plays critical role in regulating glioblastoma development. Targeting B4GalT1 for the treatment of glioblastoma is a highly viable approach that has to be further validated.

BellBrook’s Transcreener UDP2 Assay is a universal UDP detection HTS assay that utilizes a fluorescence-based method to measure glycosyltransferase activity by detecting UDP production.

How the Transcreener UDP2 Assay can facilitate B4GalT1 research:

  • Evaluate enzymatic activity
  • Screen for small molecule inhibitors
  • Determine inhibitor potency/ IC50 values
  • Profile inhibitor selectivity
  • Support mechanistic studies

References

  1. Qasba, P. K., Ramakrishnan, B. & Boeggeman, E. Structure and Function of β-1,4-Galactosyltransferase. Curr Drug Targets 9, 292–309 (2008).
  2. Kremer, J., Brendel, C., Mack, E. K. M. & Mack, H. I. D. Expression of β-1,4-galactosyltransferases during Aging in Caenorhabditis elegans. GER 66, 571–581 (2020).
  3. De Vitis, C. et al. B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells. Journal of Clinical Medicine 8, 1928 (2019).
  4. Xie, H. et al. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. BMC Cancer 18, 590 (2018).
  5. Di Buduo, C. A. et al. Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. Blood 137, 2085–2089 (2021).
  6. Holland, E. C. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci U S A 97, 6242–6244 (2000).
  7. Wang, P., Li, X. & Xie, Y. B4GalT1 Regulates Apoptosis and Autophagy of Glioblastoma In Vitro and In Vivo. Technol Cancer Res Treat 19, 1533033820980104 (2020).
Tagged under: B4GalT1 Assay, Glioblastoma Research, Transcreener UDP Assay

What you can read next

Ensuring Assay Success: The Right Plate Makes All The Difference
ST6GAL1 Drug Discovery
ST6GAL1 Drug Discovery to Combat Cancer
New Application Note: High Throughput GEF Assay using the Transcreener GDP Assay

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • DDX17 Acting in Viral Innate Immunity

    DDX17 as a Dynamic Helicase in Innate Immunity

    DDX17 (p72/p82) was first detected as a bunyavi...
  • DNMT3A Actions in Epigenetics

    Unpuzzling DNMT3A as a Key Epigenetic Player

    DNA methyltransferase 3-alpha (DNMT3A) effects ...
  • METTL3 Acts as a Tumor Promoter

    METTL3 is a Significant Focus in Cancer Research

    Methyltransferase-like 3 (METTL3) is a 70 kDa p...
  • RNA Methyltransferase METTL16 Performing Many Functions

    METTL16: An RNA Methyltransferase That Wears Many Hats

    Methyltransferase-like protein 16 (METTL16) is ...
  • Researchers Identify PDE5 Inhibitor Using Transcreener Assay

    Researchers Use Transcreener Assay to Identify New PDE5 Inhibitor

    Phosphodiesterase 5 (PDE5) is most familiar in ...

Archives

BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP